Update on childhood rhabdomyosarcoma.
The overall survival of childhood rhabdomyosarcoma has improved dramatically over the past 10 years. Early diagnosis and appropriate referral to a specialised centre leading to an accurate and timely diagnosis reflects on overall outcome. Recent molecular studies have identified different biological subtypes resulting in the recognition of poorer subgroups and allowing more appropriate treatment to be administered. Clinical trials remain the cornerstone to further improve outcome, now carried out on an international basis.
McDowell
H P
HP
RLC NHS Trust Alder Hey, Liverpool, UK Dr H P McDowell, Consultant Paediatric Oncologist, RLC NHS Trust Alder Hey, Eaton Road, Liverpool L12 2AP, UK. Heather.McDowell@RLCH.NWEST.NHS.UK
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D006801:Humans; D012208:Rhabdomyosarcoma / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D015996:Survival Rate; D014178:Translocation, Genetic; D016896:Treatment Outcome
D000970:Antineoplastic Agents